Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022 - … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
April 7, 2022 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Update on Regulatory Submission for Aducanumab in the European Union
April 22, 2022 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … of, and expectations for, Biogen’s commercial business and pipeline programs, including ADUHELM; planning and timing for … disease; the potential of Biogen’s commercial business and pipeline programs, including ADUHELM; and risks and …
Biogen Names Christopher Viehbacher President and Chief Executive Officer
November 10, 2022 - … leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders. … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment … leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders. …
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
October 17, 2022 - … sensitive clinical endpoints. Today, the company has a pipeline of investigational drugs being evaluated in ALS, … of ALS; the potential of our commercial business and pipeline programs, including tofersen; and risks and … sensitive clinical endpoints. Today, the company has a pipeline of investigational drugs being evaluated in ALS, …
Biogen and Sage Therapeutics Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
October 17, 2022 - … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … on advancing one of the industry’s most diversified pipeline in neuroscience that will transform the standard of …
